Cougar Biotechnology, Inc. Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that positive Phase I and Phase II data on the Company’s prostate cancer drug candidate CB7630 (abiraterone acetate) were presented at the European Society for Medical Oncology (ESMO) Conference, which is currently taking place in Lugano, Switzerland. The data were presented in two oral and poster presentations on Sunday, July 8, as part of the session for genitourinary (prostate) cancer that took place. The poster presentations are further detailed below:

MORE ON THIS TOPIC